Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy C4 Therapeutics stock (C4 Therapeutics)

Buy C4 Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

C4 Therapeutics is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.00 – a decrease of 4% over the previous week. C4 Therapeutics employs 145 staff and has a trailing 12-month revenue of around $29.4 million.

Our top picks for where to buy C4 Therapeutics Inc stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy C4 Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CCCC. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy C4 Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

C4 Therapeutics stock price (NASDAQ: CCCC)

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

Information last updated 2024-10-24.
Latest market close$6.00
52-week range$1.06 - $11.88
50-day moving average $6.05
200-day moving average $6.50
Wall St. target price$16.14
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-1.87

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

C4 Therapeutics price performance over time

Historical closes compared with the close of $5.89 from 2024-10-25

1 week (2024-10-22) -5.15%
1 month (2024-09-27) 5.89
3 months (2024-07-29) -9.94%
6 months (2024-04-29) -6.80%
1 year (2023-10-27) 323.74%
2 years (2022-10-28) -38.26%
3 years (2021-10-29) 44.42
5 years (2019-10-25) N/A

C4 Therapeutics financials

Revenue TTM $29.4 million
Gross profit TTM $-86,745,000
Return on assets TTM -19.25%
Return on equity TTM -44.87%
Profit margin 0%
Book value $3.59
Market Capitalization $418.8 million

TTM: trailing 12 months

C4 Therapeutics share dividends

We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

C4 Therapeutics share price volatility

Over the last 12 months, C4 Therapeutics's shares have ranged in value from as little as $1.06 up to $11.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics's is 3.052. This would suggest that C4 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put C4 Therapeutics's beta into context you can compare it against those of similar companies.

C4 Therapeutics overview

C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ; Biogen MA, Inc.

Frequently asked questions

null
What percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 11.655% of C4 Therapeutics shares are held by insiders and 88.526% by institutions.
How many people work for C4 Therapeutics?
Latest data suggests 145 work at C4 Therapeutics.
When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December.
Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472
What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site